Know Cancer

forgot password

An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

Phase 2
18 Years
Not Enrolling
Advanced Gastric Cancer

Thank you

Trial Information

An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

Inclusion Criteria:

Patients eligible for inclusion in this study have to meet all of the following criteria:

1. Written informed consent obtained prior to any screening procedures

2. Patients with documented cytological or histological confirmed gastric adenocarcinoma
or gastroesophageal junction adenocarcinoma and proven HER2 positive.

3. Patients with progressive disease (radiological confirmation required according to
RECIST) after first line of trastuzumab in combination with chemotherapy for advanced
gastric cancer.

4. Age ≥ 18 years or age of consent in country of residence and able to sign Informed

5. ECOG performance status of 0-1 at study entry

6. HER2-overexpressing positive gastric tumor by IHC3+ or IHC2+ with positive in situ

7. Measurable disease according to RECIST (Irradiated lesions can not be considered
measurable unless they have clearly progressed since radiotherapy).

8. Negative serum pregnancy test. The serum pregnancy test must be obtained prior to any
drug administration (≤ 72 hours prior to dosing) in all pre-menopausal women and for
women < 2 years after the onset of menopause.

9. Patients must have the following laboratory values:


- Absolute Neutrophil Count (ANC) ≥1.5x109/L,

- Hemoglobin (Hgb) ≥ 9 g/dL,

- Platelets (plt) ≥100x109/L


- Serum total bilirubin ≤ 1.5 x ULN

- Serum albumin > 2.5 g/dl

- Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 ml/min.

- AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 x ULN if liver
metastases are present

Exclusion Criteria:

Patients eligible for this study must not meet any of the following criteria:

1. Evidence of spinal cord compression or current evidence of CNS metastases. CT/MRI of
the brain is mandatory (within 3 weeks before study start) in case of clinical
suspicion or evidence of brain metastases

2. Patient who are < 4 weeks since last chemotherapy or treatment with another systemic
anti-cancer agent. Patients must have recovered (CTC ≤ 1) from acute toxicities of
any previous therapy (with the exception of alopecia).

3. Patients may have received prior radiotherapy for management of local disease
providing that disease progression has been documented, all toxicities have resolved
(CTC ≤ 1) (with the exception of alopecia), and the last fraction of radiotherapy was
completed at least 4 weeks prior to the study.

4. Prior treatment with an agent that acts via HER2/c-erbB2 targeting other than 1st
line trastuzumab, include (but are not limited to) lapatinib and pertuzumab.

5. Treatment with therapeutic doses of coumarin-type anticoagulants. (Maximum daily dose
of 2 mg, for line patency permitted)

6. Patients with malignant ascites that require invasive treatment

7. Patients with acute or chronic renal disease; and active and chronic liver disease
requiring intervention. Other concurrent severe and/or uncontrolled medical
conditions that could cause unacceptable safety risks or compromise compliance with
the protocol.

8. Major surgery ≤ 2 weeks prior to enrollment or who have not recovered from such

9. Impaired cardiac function

10. Concurrent malignancies or invasive cancers diagnosed within the past 5 years, except
for adequately treated basal cell cancer of the skin or in situ cancer of the cervix

11. Patients receiving chronic or high dose corticosteroids therapy (Inhaled steroids and
short courses of oral steroids for anti-emesis or as an appetite stimulant are

12. Patients unwilling or unable to comply with the protocol

13. Patients known to be HIV positive. Testing is not required in the absence of clinical
signs and symptoms suggesting HIV infection.

14. Known hypersensitivity to any of the study drugs or their excipients

15. Participation in another clinical study within 30 days before first study treatment

16. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
female after conception and until the termination of gestation, confirmed by a
positive hCG laboratory test (> 5 mIU/mL).

17. Fertile women of childbearing potential (WOCBP) not using adequate contraception
(abstinence, oral contraceptives, intrauterine device or barrier method of
contraception in conjunction with spermicidal jelly or surgically sterile).

Type of Study:


Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

efficacy of AUY922 in combination with trastuzumab as assessed by RECIST

Outcome Time Frame:

every 6 weeks

Safety Issue:


Principal Investigator

Novartis Pharmaceuticals

Investigator Role:

Study Director

Investigator Affiliation:

Novartis Pharmaceuticals


United States: Food and Drug Administration

Study ID:




Start Date:

November 2011

Completion Date:

September 2013

Related Keywords:

  • Advanced Gastric Cancer
  • HER2+,
  • Gastric Cancer,
  • HSP90,
  • 2nd-line,
  • Trastuzumab
  • Stomach Neoplasms



UCLA/ University of California Los Angeles UCLA LeConte LocationLos Angeles, California  90095
Clinical Research AllianceLake Success, New York  11042
MD Anderson Cancer Center/University of Texas UT SCHouston, Texas  77030-4009